Atom Investors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Atom Investors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.26M	Buy	+40,026	New	+$2.33M	0.16%	216
2025 Q4	–	Sell	-5,878	Closed	-$318K	–	598
2025 Q3	$318K	Buy	+5,878	New	+$336K	0.02%	436
2023 Q4	–	Sell	-4,145	Closed	-$367K	–	457
2023 Q3	$367K	Buy	+4,145	New	+$369K	0.08%	283
2020 Q1	–	Sell	-12,397	Closed	-$1.05M	–	320
2019 Q4	$1.05M	Sell	12,397 -43,306	-78%	-$3.27M	0.09%	152
2019 Q3	$3.75M	Sell	55,703 -9,601	-15%	-$739K	0.26%	121
2019 Q2	$5.59M	Buy	+65,304	New	+$5.59M	0.36%	86

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Atom Investors's BMRN Position: Q1 2026 in Review

Atom Investors opened a new position in BioMarin Pharmaceuticals (BMRN) in Q1 2026: 40,026 shares worth $2.26M. The stake represents 0.16% of the portfolio and ranks #216 among its holdings. This is a return to the name: Atom Investors previously reported a position in BMRN as recently as Q3 2025.

Atom Investors first reported a position in BMRN in Q2 2019 and has held it in 6 quarters since. The position peaked at $5.59M in Q2 2019. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Atom Investors held 40,026 shares of BioMarin Pharmaceuticals worth $2.26M as of Q1 2026.
BioMarin Pharmaceuticals was a new Atom Investors position in Q1 2026.
BioMarin Pharmaceuticals made up 0.16% of Atom Investors's portfolio in Q1 2026, its #216 holding.
Atom Investors first reported a position in BioMarin Pharmaceuticals in Q2 2019 and has held it in 6 quarters since.
Atom Investors's BioMarin Pharmaceuticals position peaked at $5.59M in Q2 2019.
554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Atom Investors's 13F filing for Q1 2026, filed 15 May 2026.